A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD)
- 8 November 2018
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in American Journal Of Gastroenterology
- Vol. 114 (3), 472-482
- https://doi.org/10.1038/s41395-018-0272-8
Abstract
Telemedicine has shown promise in inflammatory bowel disease (IBD). The objective of this study was to compare disease activity and quality of life (QoL) in a 1 year randomized trial of IBD patients receiving telemedicine versus standard care. Patients with worsening symptoms in the prior 2 years were eligible for randomization to telemedicine (monitoring via texts EOW or weekly) or standard care. The primary outcomes were the differences in change in disease activity and QoL between the groups; change in health care utilization among groups was a secondary aim. 348 participants were enrolled (117 control group, 115 TELE-IBD EOW, and 116 TELE-IBD weekly). 259 (74.4%) completed the study. Age was 38.9 ± 12.3 years, 56.6% were women, 91.9% were Caucasian, 67.9% had Crohn’s disease (CD) and 42.5% had active disease at baseline. In CD, all groups experienced a decrease in disease activity (control −5.2 ± 5.0 to 3.7 ± 3.6, TELE-IBD EOW 4.7 ± 4.1 to 4.2 ± 3.9, and TELE-IBD weekly 4.2 ± 4.2 to 3.2 ± 3.4, p < 0.0001 for each of the groups) In UC, only controls had a significant decrease in disease activity (control 2.9 ±;3.1 to 1.4 ± 1.4, p = 0.01, TELE-IBD EOW 2.7 ± 3.1 to 1.7 ± 1.9, p = 0.35, and TELE-IBD Weekly 2.5 ± 2.5 to 2.0 ± 1.8, p = 0.31). QoL increased in all groups; the increase was significant only in TELE-IBD EOW (control 168.1 ± 34.0 to 179.3 ± 28.2, p = 0.06, TELE-IBD EOW 172.3 ± 33.1 to 181.5 ± 28.2, p = 0.03, and TELE-IBD Weekly 172.3 ± 34.5 to 179.2 ± 32.8, p = 0.10). Unadjusted and adjusted changes in disease activity and QoL were not significantly different among groups. Health care utilization increased in all groups. TELE-IBD weekly were less likely to have IBD-related hospitalizations and more likely to have non-invasive diagnostic tests and electronic encounters compared to controls; both TELE-IBD groups had decreased non-IBD related hospitalizations and increased telephone calls compared to controls. Disease activity and QoL, although improved in all participants, were not improved further through use of the TELE-IBD system. TELE-IBD participants experienced a decrease in hospitalizations with an associated increase in non-invasive diagnostic tests, telephone calls and electronic encounters. Research is needed to determine if TELE-IBD can be improved through patient engagement and whether it can decrease healthcare utilization by replacing standard care.Keywords
This publication has 36 references indexed in Scilit:
- Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT)*Inflammatory Bowel Diseases, 2012
- Utilization of healthcare resources by U.S. children and adults with inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Home Telemanagement for Patients with Ulcerative Colitis (UC HAT)Digestive Diseases and Sciences, 2008
- The Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative ColitisJournal of Occupational and Environmental Medicine, 2008
- Feasibility and Acceptance of a Home Telemanagement System in Patients with Inflammatory Bowel Disease: A 6-Month Pilot StudyDigestive Diseases and Sciences, 2007
- Polypharmacy and Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2005
- A simple clinical colitis activity indexGut, 1998
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980
- A Comparison of Oral Prednisolone Given as Single or Multiple Daily Doses for Active ProctocolitisScandinavian Journal of Gastroenterology, 1978